WOONSOCKET, R.I., Feb. 9, 2016 /PRNewswire/ --
Fourth Quarter Year-over-year Highlights:
Full Year Highlights:
2016 Guidance:
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2015.
Revenues
Net revenues for the three months ended December 31, 2015 increased 11.0%, or $4.1 billion to $41.1 billion, up from $37.1 billion in the three months ended December 31, 2014. For the year ended December 31, 2015, total net revenues increased 10.0%, or $13.9 billion to $153.3 billion, compared to $139.4 billion for the year ended December 31, 2014.
Revenues in the Pharmacy Services Segment increased 11.1% to $26.5 billion in the three months ended December 31, 2015. This increase was primarily driven by growth in specialty pharmacy, which includes the impact of the Omnicare, Inc. ("Omnicare") acquisition in August 2015, and pharmacy network claims. Pharmacy network claims processed during the three months ended December 31, 2015, increased 7.2% to 237.4 million, compared to 221.6 million in the prior year period. The increase in pharmacy network claim volume was primarily due to net new business. Mail choice claims processed during the three months ended December 31, 2015 increased approximately 3.9% to 22.2 million, compared to 21.3 million in the prior year period. The increase in the mail choice claim volume was primarily driven by specialty and continued adoption of our Maintenance Choice® offerings, partially offset by a decline in traditional mail volume. For the year ended December 31, 2015, total net revenues in the Pharmacy Services Segment increased 13.5% to $100.4 billion, compared to $88.4 billion in the year ended December 31, 2014.
Revenues in the Retail/LTC Segment increased 12.5% to $19.9 billion in the three months ended December 31, 2015. Approximately half of the increase was driven by the addition of long-term care ("LTC") operations acquired as part of the Omnicare acquisition. Same store sales increased 3.5% over the prior year period, with pharmacy same store sales up 5.0% and front store same store sales down 0.5%. Front store same store sales were negatively impacted by softer customer traffic, partially offset by an increase in basket size. Pharmacy same store prescription volumes rose 5.0% on a 30-day equivalent basis. Pharmacy same store sales were negatively impacted by approximately 470 basis points due to recent generic introductions. For the year ended December 31, 2015, total net revenues in the Retail/LTC Segment increased 6.2% to $72.0 billion, compared to $67.8 billion in the year ended December 31, 2014. Same store sales increased 1.7% for the year ended December 31, 2015, over the prior year, with pharmacy same store sales up 4.5% and front store same store sales down 5.0%. Front store same store sales would have been approximately 520 basis points higher if tobacco and the estimated associated basket sales were excluded from the year ended December 31, 2014.
For the three months ended December 31, 2015, the generic dispensing rate increased approximately 165 basis points to 83.7% in our Pharmacy Services Segment and increased approximately 155 basis points to 84.0% in our Retail/LTC Segment, compared to the prior year.
Operating Profit and Income from Continuing Operations
For the three months ended December 31, 2015, operating profit increased $243 million in the Pharmacy Services Segment and $299 million in the Retail/LTC Segment. The Pharmacy Services Segment operating profit grew 26.8% and the Retail/LTC Segment operating profit grew 19.8%(1), excluding acquisition-related integration costs of $52 million. Both segments benefited from the Omnicare acquisition, increased generic drugs dispensing rates and favorable purchasing economics. The Pharmacy Services Segment was also positively affected by growth in specialty pharmacy and pharmacy network volume, partially offset by client price compression. The Retail/LTC Segment was also positively affected by increased sales, an improved front store margin rate, partially offset by continued reimbursement pressure. The Corporate Segment includes $20 million of acquisition-related transaction and integration costs for the three months ended December 31, 2015, related to the acquisition of Omnicare and the acquisition of the pharmacies and clinics of Target Corporation ("Target"), as well as a $90 million charge related to a legacy lawsuit challenging the 1999 settlement by MedPartners of various securities class actions and a related derivative claim.
For the year ended December 31, 2015, operating profit increased by $475 million in the Pharmacy Services Segment and by $368 million in the Retail/LTC Segment. The Pharmacy Services Segment grew 13.5% and the Retail/LTC Segment grew 6.4%(1), excluding acquisition-related integration costs of $64 million. The drivers of the increases are the same as those described for the three months ended December 31, 2015 above. The Corporate Segment includes $156 million of acquisition-related transaction and integration costs for the year ended December 31, 2015 related to the acquisition of Omnicare and the acquisition of the pharmacies and clinics of Target, as well as the $90 million legal charge.
Income from continuing operations for the three months ended December 31, 2015 was $1.5 billion, an increase of $178 million or 13.4%, compared to the prior year. Income from continuing operations for the year ended December 31, 2015 was $5.2 billion, an increase of $585 million or 12.6%, compared to the prior year.
Adjusted earnings per share ("Adjusted EPS") for the three months ended December 31, 2015 and 2014, was $1.53 and $1.21, respectively, an increase of 26.5%. Adjusted EPS excludes $191 million and $128 million of intangible asset amortization for the three months ended December 31, 2015 and 2014, respectively. Adjusted EPS also excludes $72 million of acquisition-related transaction and integration costs and the $90 million legal charge. GAAP earnings per diluted share ("GAAP EPS") for the three months ended December 31, 2015 was $1.34, compared to $1.14 in the prior year.
Adjusted EPS for the years ended December 31, 2015 and 2014, was $5.16 and $4.49, respectively, an increase of 14.8%. Adjusted EPS excludes $611 million and $518 million of intangible asset amortization for the years ended December 31, 2015 and 2014, respectively. Adjusted EPS in 2015 also excludes $272 million of acquisition-related bridge financing, transaction and integration costs and the $90 million legal charge, and in 2014 excludes the loss on early extinguishment of debt. GAAP EPS for the year ended December 31, 2015 was $4.62, compared to $3.96 in the prior year.
President and CEO Larry Merlo, stated, "We enjoyed a successful year in 2015, highlighted by excellent performance across our enterprise and two key acquisitions that support our strategy for growth. We grew our core business with the acquisition of Target's pharmacies and clinics and expanded our reach with the acquisition of Omnicare, the leader in long-term care pharmacy. At the same time, we achieved solid year-over-year growth in revenues, operating profit, and earnings per share. We also generated $6.4 billion in free cash flow for the full-year, exceeding our expectations. Through dividends and share repurchases, we returned more than $6 billion to our shareholders in 2015. As expected, growth in the fourth quarter was especially strong, with revenues increasing 11% and Adjusted EPS increasing 26.5%, right in line with our guidance."
Mr. Merlo continued, "We continue to win and gain share across our businesses and I'm very pleased with the outstanding PBM selling season we had for 2016, with gross client wins of $14.8 billion. Our growth in the fast-growing specialty market continues to outpace the industry. Overall, our leadership in multiple competencies enables us to provide superior value for patients, payors, and providers. We firmly believe that we have the right strategy for success in the evolving health care marketplace."
Guidance
The Company confirmed its previous guidance for the full year and first quarter of 2016. The Company expects to deliver Adjusted EPS of $5.73 to $5.88 and GAAP diluted earnings per share from continuing operations of $5.28 to $5.43 in 2016. The Company also confirmed its first quarter Adjusted EPS guidance of $1.14 to $1.17 and GAAP diluted earnings per share from continuing operations of $1.03 to $1.06. Adjusted EPS excludes intangible asset amortization and guidance also excludes the affect of acquisition-related integration costs that are expected to occur during 2016. The Company confirmed its 2016 free cash flow guidance of $5.3 to $5.6 billion, and its 2015 cash flow from operations guidance of $7.6 to $7.9 billion. These 2016 guidance estimates assume the completion of $4.0 billion in share repurchases.
Real Estate Program
During the three months ended December 31, 2015, the Company opened 53 new retail stores, acquired 1,672 pharmacies and closed 14 retail stores. In addition, the Company relocated 19 retail stores. As of December 31, 2015, the Company operated 9,655 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil.
Teleconference and Webcast
The Company will be holding a conference call today for the investment community at 8:30 am (EST) to discuss its quarterly and annual results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.
About CVS Health
CVS Health is a pharmacy innovation company helping people on their path to better health. Through its approximately 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 75 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
| (1) |
Excluding $52 million of acquisition-related integration costs, operating profit for the Retail/LTC Segment increased $351 million, or 19.8%, from $1,780 million for the three months ended December 31, 2014 to $2,131 million for the three months ended December 31, 2015. Excluding $64 million of acquisition-related integration costs, operating profit for the Retail/LTC Segment increased $432 million, or 6.4%, from $6,762 million for the year ended December 31, 2014 to $7,194 million for the year ended December 31, 2015. |
| — Tables Follow — |
||||||||||||||||
| CVS HEALTH CORPORATION |
||||||||||||||||
| Condensed Consolidated Statements of Income |
||||||||||||||||
| (Unaudited) |
||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| In millions, except per share amounts |
2015 |
2014 |
2015 |
2014 |
||||||||||||
| Net revenues |
$ |
41,145 |
$ |
37,055 |
$ |
153,290 |
$ |
139,367 |
||||||||
| Cost of revenues |
33,844 |
30,422 |
126,762 |
114,000 |
||||||||||||
| Gross profit |
7,301 |
6,633 |
26,528 |
25,367 |
||||||||||||
| Operating expenses |
4,572 |
4,312 |
17,074 |
16,568 |
||||||||||||
| Operating profit |
2,729 |
2,321 |
9,454 |
8,799 |
||||||||||||
| Interest expense, net |
276 |
131 |
838 |
600 |
||||||||||||
| Loss on early extinguishment of debt |
— |
— |
— |
521 |
||||||||||||
| Income before income tax provision |
2,453 |
2,190 |
8,616 |
7,678 |
||||||||||||
| Income tax provision |
953 |
868 |
3,386 |
3,033 |
||||||||||||
| Income from continuing operations |
1,500 |
1,322 |
5,230 |
4,645 |
||||||||||||
| Income (loss) from discontinued operations, net of tax |
(1) |
(1) |
9 |
(1) |
||||||||||||
| Net income |
1,499 |
1,321 |
5,239 |
4,644 |
||||||||||||
| Net income attributable to noncontrolling interest |
(1) |
— |
(2) |
— |
||||||||||||
| Net income attributable to CVS Health |
$ |
1,498 |
$ |
1,321 |
$ |
5,237 |
$ |
4,644 |
||||||||
| Income from continuing operations attributable to CVS Health: |
||||||||||||||||
| Income from continuing operations |
$ |
1,500 |
$ |
1,322 |
$ |
5,230 |
$ |
4,645 |
||||||||
| Net income attributable to noncontrolling interest |
(1) |
— |
(2) |
— |
||||||||||||
| Income from continuing operations attributable to CVS Health |
$ |
1,499 |
$ |
1,322 |
$ |
5,228 |
$ |
4,645 |
||||||||
| Basic earnings per share: |
||||||||||||||||
| Income from continuing operations attributable to CVS Health |
$ |
1.35 |
$ |
1.15 |
$ |
4.65 |
$ |
3.98 |
||||||||
| Income from discontinued operations attributable to CVS Health |
$ |
— |
$ |
— |
$ |
0.01 |
$ |
— |
||||||||
| Net income attributable to CVS Health |
$ |
1.35 |
$ |
1.15 |
$ |
4.66 |
$ |
3.98 |
||||||||
| Weighted average basic shares outstanding |
1,107 |
1,143 |
1,118 |
1,161 |
||||||||||||
| Diluted earnings per share: |
||||||||||||||||
| Income from continuing operations attributable to CVS Health |
$ |
1.34 |
$ |
1.14 |
$ |
4.62 |
$ |
3.96 |
||||||||
| Income from discontinued operations attributable to CVS Health |
$ |
— |
$ |
— |
$ |
0.01 |
$ |
— |
||||||||
| Net income attributable to CVS Health |
$ |
1.34 |
$ |
1.14 |
$ |
4.63 |
$ |
3.96 |
||||||||
| Weighted average diluted shares outstanding |
1,114 |
1,152 |
1,126 |
1,169 |
||||||||||||
| Dividends declared per share |
$ |
0.35 |
$ |
0.275 |
$ |
1.40 |
$ |
1.10 |
||||||||
| CVS HEALTH CORPORATION |
||||||||
| Condensed Consolidated Balance Sheets |
||||||||
| (Unaudited) |
||||||||
| December 31, |
||||||||
| In millions, except per share amounts |
2015 |
2014 |
||||||
| Assets: |
||||||||
| Cash and cash equivalents |
$ |
2,459 |
$ |
2,481 |
||||
| Short-term investments |
88 |
34 |
||||||
| Accounts receivable, net |
11,888 |
9,687 |
||||||
| Inventories |
14,001 |
11,930 |
||||||
| Deferred income taxes |
1,220 |
985 |
||||||
| Other current assets |
722 |
866 |
||||||
| Total current assets |
30,378 |
25,983 |
||||||
| Property and equipment, net |
9,855 |
8,843 |
||||||
| Goodwill |
38,106 |
28,142 |
||||||
| Intangible assets, net |
13,878 |
9,774 |
||||||
| Other assets |
1,440 |
1,445 |
||||||
| Total assets |
$ |
93,657 |
$ |
74,187 |
||||
| Liabilities: |
||||||||
| Accounts payable |
$ |
7,490 |
$ |
6,547 |
||||
| Claims and discounts payable |
7,653 |
5,404 |
||||||
| Accrued expenses |
6,829 |
5,816 |
||||||
| Short-term debt |
— |
685 |
||||||
| Current portion of long-term debt |
1,197 |
575 |
||||||
| Total current liabilities |
23,169 |
19,027 |
||||||
| Long-term debt |
26,267 |
11,630 |
||||||
| Deferred income taxes |
5,437 |
4,036 |
||||||
| Other long-term liabilities |
1,542 |
1,531 |
||||||
| Commitments and contingencies |
— |
— |
||||||
| Redeemable noncontrolling interest |
39 |
— |
||||||
| Shareholders' equity: |
||||||||
| CVS Health shareholders' equity: |
||||||||
| Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding |
— |
— |
||||||
| Common stock, par value $0.01: 3,200 shares authorized; 1,699 shares issued and |
||||||||
| 1,101 shares outstanding at December 31, 2015 and 1,691 shares issued and 1,140 |
||||||||
| shares outstanding at December 31, 2014 |
17 |
17 |
||||||
| Treasury stock, at cost: 597 shares at December 31, 2015 and 550 shares |
||||||||
| at December 31, 2014 |
(28,886) |
(24,078) |
||||||
| Shares held in trust: 1 share at December 31, 2015 and 2014 |
(31) |
(31) |
||||||
| Capital surplus |
30,948 |
30,418 |
||||||
| Retained earnings |
35,506 |
31,849 |
||||||
| Accumulated other comprehensive income (loss) |
(358) |
(217) |
||||||
| Total CVS Health shareholders' equity |
37,196 |
37,958 |
||||||
| Noncontrolling interest |
7 |
5 |
||||||
| Total shareholders' equity |
37,203 |
37,963 |
||||||
| Total liabilities and shareholders' equity |
$ |
93,657 |
$ |
74,187 |
||||
| CVS HEALTH CORPORATION |
||||||||
| Condensed Consolidated Statements of Cash Flows |
||||||||
| (Unaudited) |
||||||||
| Year Ended December 31, |
||||||||
| In millions |
2015 |
2014 |
||||||
| Cash flows from operating activities: |
||||||||
| Cash receipts from customers |
$ |
148,954 |
$ |
132,406 |
||||
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies |
(122,498) |
(105,362) |
||||||
| Cash paid to other suppliers and employees |
(14,162) |
(15,344) |
||||||
| Interest received |
21 |
15 |
||||||
| Interest paid |
(629) |
(647) |
||||||
| Income taxes paid |
(3,274) |
(2,931) |
||||||
| Net cash provided by operating activities |
8,412 |
8,137 |
||||||
| Cash flows from investing activities: |
||||||||
| Purchases of property and equipment |
(2,367) |
(2,136) |
||||||
| Proceeds from sale-leaseback transactions |
411 |
515 |
||||||
| Proceeds from sale of property and equipment and other assets |
35 |
11 |
||||||
| Acquisitions (net of cash acquired) and other investments |
(11,475) |
(2,439) |
||||||
| Purchase of available-for-sale investments |
(267) |
(157) |
||||||
| Maturity of available-for-sale investments |
243 |
161 |
||||||
| Net cash used in investing activities |
(13,420) |
(4,045) |
||||||
| Cash flows from financing activities: |
||||||||
| (Decrease) increase in short-term debt |
(685) |
685 |
||||||
| Proceeds from issuance of long-term debt |
14,805 |
1,483 |
||||||
| Repayments of long-term debt |
(2,902) |
(3,100) |
||||||
| Payment of contingent consideration |
(58) |
— |
||||||
| Dividends paid |
(1,576) |
(1,288) |
||||||
| Proceeds from exercise of stock options |
299 |
421 |
||||||
| Excess tax benefits from stock-based compensation |
127 |
106 |
||||||
| Repurchase of common stock |
(5,001) |
(4,001) |
||||||
| Other |
(3) |
— |
||||||
| Net cash provided by (used in) financing activities |
5,006 |
(5,694) |
||||||
| Effect of exchange rates on cash |
(20) |
(6) |
||||||
| Net decrease in cash and cash equivalents |
(22) |
(1,608) |
||||||
| Cash and cash equivalents at the beginning of the year |
2,481 |
4,089 |
||||||
| Cash and cash equivalents at the end of the year |
$ |
2,459 |
$ |
2,481 |
||||
| Reconciliation of net income to net cash provided by operating activities: |
||||||||
| Net income |
$ |
5,239 |
$ |
4,644 |
||||
| Adjustments required to reconcile net income to net cash provided by operating activities: |
||||||||
| Depreciation and amortization |
2,092 |
1,931 |
||||||
| Stock-based compensation |
230 |
165 |
||||||
| Loss on early extinguishment of debt |
— |
521 |
||||||
| Deferred income taxes and other non-cash items |
(266) |
(58) |
||||||
| Change in operating assets and liabilities, net of effects of acquisitions: |
||||||||
| Accounts receivable, net |
(1,594) |
(737) |
||||||
| Inventories |
(1,141) |
(770) |
||||||
| Other current assets |
355 |
(383) |
||||||
| Other assets |
2 |
9 |
||||||
| Accounts payable and claims and discounts payable |
2,834 |
1,742 |
||||||
| Accrued expenses |
765 |
1,060 |
||||||
| Other long-term liabilities |
(104) |
13 |
||||||
| Net cash provided by operating activities |
$ |
8,412 |
$ |
8,137 |
||||
| Adjusted Earnings Per Share |
||||||||||||||||
| (Unaudited) |
||||||||||||||||
| The Company is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the Company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP. |
||||||||||||||||
| The following is a reconciliation of income before income tax provision to Adjusted earnings per share: |
||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| In millions, except per share amounts |
2015 |
2014 |
2015 |
2014 |
||||||||||||
| Income before income tax provision |
$ |
2,453 |
$ |
2,190 |
$ |
8,616 |
$ |
7,678 |
||||||||
| Non-GAAP adjustments: |
||||||||||||||||
| Amortization of intangible assets |
191 |
128 |
611 |
518 |
||||||||||||
| Acquisition-related bridge financing costs(1) |
— |
— |
52 |
— |
||||||||||||
| Acquisition-related transaction and integration costs(1) |
72 |
— |
220 |
— |
||||||||||||
| Charge related to a disputed 1999 legal settlement |
90 |
— |
90 |
— |
||||||||||||
| Loss on early extinguishment of debt |
— |
— |
— |
521 |
||||||||||||
| Adjusted income before income tax provision |
2,806 |
2,318 |
9,589 |
8,717 |
||||||||||||
| Adjusted income tax provision |
1,093 |
919 |
3,750 |
3,444 |
||||||||||||
| Adjusted income from continuing operations |
1,713 |
1,399 |
5,839 |
5,273 |
||||||||||||
| Net income attributable to noncontrolling interest |
(1) |
— |
(2) |
— |
||||||||||||
| Income allocable to participating securities |
(8) |
(6) |
(27) |
(19) |
||||||||||||
| Adjusted income from continuing operations attributable to CVS Health |
$ |
1,704 |
$ |
1,393 |
$ |
5,810 |
$ |
5,254 |
||||||||
| Weighted average diluted shares outstanding |
1,114 |
1,152 |
1,126 |
1,169 |
||||||||||||
| Adjusted earnings per share |
$ |
1.53 |
$ |
1.21 |
$ |
5.16 |
$ |
4.49 |
||||||||
| (1) Costs associated with the acquisitions of Omnicare and the pharmacies and clinics of Target. |
||||||||||||||||
| Free Cash Flow |
||||||||
| (Unaudited) |
||||||||
| The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions). |
||||||||
| The following is a reconciliation of net cash provided by operating activities to free cash flow: |
||||||||
| Year Ended December 31, |
||||||||
| In millions |
2015 |
2014 |
||||||
| Net cash provided by operating activities(1) |
$ |
8,412 |
$ |
8,137 |
||||
| Subtract: Additions to property and equipment |
(2,367) |
(2,136) |
||||||
| Add: Proceeds from sale-leaseback transactions |
411 |
515 |
||||||
| Free cash flow |
$ |
6,456 |
$ |
6,516 |
||||
| (1) Cash provided by operating activities for the year ended December 31, 2015 includes $52 million of pre-tax acquisition-related bridge financing costs and $220 million of pre-tax acquisition-related transaction and integration costs. |
||||||||
| Supplemental Information |
||||||||||||||||||||
| (Unaudited) |
||||||||||||||||||||
| The Company evaluates its Pharmacy Services and Retail/LTC segment performance based on net revenues, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements: |
||||||||||||||||||||
| In millions |
Pharmacy Services Segment(1) |
Retail/LTC Segment |
Corporate Segment |
Intersegment Eliminations(2) |
Consolidated Totals |
|||||||||||||||
| Three Months Ended |
||||||||||||||||||||
| December 31, 2015: |
||||||||||||||||||||
| Net revenues |
$ |
26,514 |
$ |
19,903 |
$ |
— |
$ |
(5,272) |
$ |
41,145 |
||||||||||
| Gross profit |
1,492 |
6,002 |
— |
(193) |
7,301 |
|||||||||||||||
| Operating profit (loss)(3) |
1,152 |
2,079 |
(325) |
(177) |
2,729 |
|||||||||||||||
| December 31, 2014: |
||||||||||||||||||||
| Net revenues |
23,874 |
17,698 |
— |
(4,517) |
37,055 |
|||||||||||||||
| Gross profit |
1,238 |
5,558 |
— |
(163) |
6,633 |
|||||||||||||||
| Operating profit (loss) |
909 |
1,780 |
(205) |
(163) |
2,321 |
|||||||||||||||
| Year Ended |
||||||||||||||||||||
| December 31, 2015: |
||||||||||||||||||||
| Net revenues |
100,363 |
72,007 |
— |
(19,080) |
153,290 |
|||||||||||||||
| Gross profit |
5,227 |
21,992 |
— |
(691) |
26,528 |
|||||||||||||||
| Operating profit (loss)(3) |
3,989 |
7,130 |
(1,037) |
(628) |
9,454 |
|||||||||||||||
| December 31, 2014: |
||||||||||||||||||||
| Net revenues |
88,440 |
67,798 |
— |
(16,871) |
139,367 |
|||||||||||||||
| Gross profit |
4,771 |
21,277 |
— |
(681) |
25,367 |
|||||||||||||||
| Operating profit (loss)(3) |
3,514 |
6,762 |
(796) |
(681) |
8,799 |
|||||||||||||||
| (1) Net revenues of the Pharmacy Services Segment include approximately $2.1 billion and $1.9 billion of retail co-payments for the three months ended December 31, 2015 and 2014, respectively, as well as $8.9 billion and $8.1 billion of retail co-payments for the year ended December 31, 2015 and 2014, respectively. |
||||||||||||||||||||
| (2) Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients ("members") fill prescriptions at retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice® elect to pick up maintenance prescriptions at a retail drugstore instead of receiving them through the mail, or when members have prescriptions filled at long-term care facilities. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis. |
||||||||||||||||||||
| (3) The Corporate Segment includes $20 million and $156 million of acquisition-related transaction and integration costs related to the acquisition of Omnicare and the pharmacy and clinics of target for the three months and year ended December 31, 2015, respectively. For the three months and year ended December 31, 2015, the Corporate Segment also included a $90 million charge related to a legacy lawsuit challenging the 1999 legal settlement by MedPartners of various securities class actions and a related derivative claim. |
||||||||||||||||||||
| Supplemental Information |
||||||||||||||||
| (Unaudited) |
||||||||||||||||
| Pharmacy Services Segment |
||||||||||||||||
| The following table summarizes the Pharmacy Services Segment's performance for the respective periods: |
||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| In millions |
2015 |
2014 |
2015 |
2014 |
||||||||||||
| Net revenues |
$ |
26,514 |
$ |
23,874 |
$ |
100,363 |
$ |
88,440 |
||||||||
| Gross profit |
$ |
1,492 |
$ |
1,238 |
$ |
5,227 |
$ |
4,771 |
||||||||
| Gross profit % of net revenues |
5.6 |
% |
5.2 |
% |
5.2 |
% |
5.4 |
% |
||||||||
| Operating expenses |
$ |
340 |
$ |
329 |
$ |
1,238 |
$ |
1,257 |
||||||||
| Operating expense % of net revenues |
1.3 |
% |
1.4 |
% |
1.2 |
% |
1.4 |
% |
||||||||
| Operating profit |
$ |
1,152 |
$ |
909 |
$ |
3,989 |
$ |
3,514 |
||||||||
| Operating profit % of net revenues |
4.3 |
% |
3.8 |
% |
4.0 |
% |
4.0 |
% |
||||||||
| Net revenues: |
||||||||||||||||
| Mail choice(1) |
$ |
10,235 |
$ |
8,440 |
$ |
37,828 |
$ |
31,081 |
||||||||
| Pharmacy network(2) |
$ |
16,198 |
$ |
15,374 |
$ |
62,240 |
$ |
57,122 |
||||||||
| Other |
$ |
81 |
$ |
60 |
$ |
295 |
$ |
237 |
||||||||
| Pharmacy claims processed: |
||||||||||||||||
| Total |
259.6 |
242.9 |
1,011.9 |
932.0 |
||||||||||||
| Mail choice(1) |
22.2 |
21.3 |
85.7 |
82.4 |
||||||||||||
| Pharmacy network(2) |
237.4 |
221.6 |
926.2 |
849.6 |
||||||||||||
| Generic dispensing rate: |
||||||||||||||||
| Total |
83.7 |
% |
82.1 |
% |
83.7 |
% |
82.2 |
% |
||||||||
| Mail choice(1) |
76.5 |
% |
75.1 |
% |
76.4 |
% |
74.6 |
% |
||||||||
| Pharmacy network(2) |
84.4 |
% |
82.7 |
% |
84.4 |
% |
83.0 |
% |
||||||||
| Mail choice penetration rate |
20.7 |
% |
21.3 |
% |
20.6 |
% |
21.4 |
% |
||||||||
| (1) Mail choice is defined as claims filled at a Pharmacy Services mail facility, which include specialty mail claims inclusive of Specialty Connect® claims filled at retail, as well as prescriptions filled at retail under the Maintenance Choice program. |
||||||||||||||||
| (2) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice®, which are included within the mail choice category. Pharmacy network is defined as claims filled at retail and specialty pharmacies, including our retail drugstores and long-term care pharmacies, but excluding Maintenance Choice activity. |
||||||||||||||||
| Supplemental Information |
||||||||||||||||
| (Unaudited) |
||||||||||||||||
| Retail/LTC Segment |
||||||||||||||||
| The following table summarizes the Retail/LTC Segment's performance for the respective periods: |
||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| In millions |
2015 |
2014 |
2015 |
2014 |
||||||||||||
| Net revenues |
$ |
19,903 |
$ |
17,698 |
$ |
72,007 |
$ |
67,798 |
||||||||
| Gross profit |
$ |
6,002 |
$ |
5,558 |
$ |
21,992 |
$ |
21,277 |
||||||||
| Gross profit % of net revenues |
30.2 |
% |
31.4 |
% |
30.5 |
% |
31.4 |
% |
||||||||
| Operating expenses(1) |
$ |
3,923 |
$ |
3,778 |
$ |
14,862 |
$ |
14,515 |
||||||||
| Operating expense % of net revenues |
19.7 |
% |
21.3 |
% |
20.6 |
% |
21.4 |
% |
||||||||
| Operating profit |
$ |
2,079 |
$ |
1,780 |
$ |
7,130 |
$ |
6,762 |
||||||||
| Operating profit % of net revenues |
10.4 |
% |
10.1 |
% |
9.9 |
% |
10.0 |
% |
||||||||
| Prescriptions filled (90 Day = 3 Rx) (2) |
287.5 |
244.8 |
1,031.6 |
935.9 |
||||||||||||
| Net revenue increase (decrease): |
||||||||||||||||
| Total |
12.5 |
% |
2.9 |
% |
6.2 |
% |
3.3 |
% |
||||||||
| Pharmacy |
16.7 |
% |
5.5 |
% |
9.5 |
% |
5.1 |
% |
||||||||
| Front store |
1.2 |
% |
(4.9)% |
(2.5)% |
(2.5)% |
|||||||||||
| Total prescription volume (90 Day = 3 Rx) (2) |
7.1 |
% |
6.7 |
% |
10.2 |
% |
5.2 |
% |
||||||||
| Same store increase (decrease)(3): |
||||||||||||||||
| Total sales |
3.5 |
% |
1.6 |
% |
1.7 |
% |
2.1 |
% |
||||||||
| Pharmacy sales |
5.0 |
% |
5.5 |
% |
4.5 |
% |
4.8 |
% |
||||||||
| Front store sales(4) |
(0.5) |
% |
(7.2) |
% |
(5.0) |
% |
(4.0)% |
|||||||||
| Prescription volume (90 Day = 3 Rx) (2) |
5.0 |
% |
5.3 |
% |
4.8 |
% |
4.1 |
% |
||||||||
| Generic dispensing rate |
84.0 |
% |
82.4 |
% |
84.5 |
% |
83.1 |
% |
||||||||
| Pharmacy % of total revenues |
73.9 |
% |
71.2 |
% |
72.9 |
% |
70.7 |
% |
||||||||
| (1) Operating expenses for the three months and year ended December 31, 2015 include $52 million and $64 million, respectively, of acquisition-related integration costs related to the acquisition of Omnicare and the pharmacies and clinics of Target. |
||||||||||||||||
| (2) Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. |
||||||||||||||||
| (3) Same store sales and prescriptions exclude revenues from MinuteClinic®, and revenue and prescriptions from stores in Brazil, long-term care operations and from commercialization services. |
||||||||||||||||
| (4) Front store same store sales would have been approximately 520 basis points higher for the year ended December 31, 2015 if tobacco and the estimated associated basket sales were excluded from the year ended December 31, 2014. |
||||||||||||||||
| Adjusted Earnings Per Share Guidance |
||||||||
| (Unaudited) |
||||||||
| The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. |
||||||||
| In millions, except per share amounts |
Year Ending December 31, 2016 |
|||||||
| Income before income tax provision(1) |
$ |
9,394 |
$ |
9,670 |
||||
| Non-GAAP adjustments: |
||||||||
| Amortization of intangible assets |
800 |
798 |
||||||
| Adjusted income before income tax provision |
10,194 |
10,468 |
||||||
| Adjusted income tax provision |
3,974 |
4,078 |
||||||
| Adjusted income from continuing operations |
6,220 |
6,390 |
||||||
| Net income attributable to noncontrolling interest |
(7) |
(7) |
||||||
| Income allocable to participating securities |
(30) |
(30) |
||||||
| Adjusted income from continuing operations attributable to CVS Health |
$ |
6,183 |
$ |
6,353 |
||||
| Weighted average diluted shares outstanding |
1,080 |
1,080 |
||||||
| Adjusted earnings per share |
$ |
5.73 |
$ |
5.88 |
||||
| In millions, except per share amounts |
Three Months Ending March 31, 2016 |
|||||||
| Income before income tax provision(1) |
$ |
1,883 |
$ |
1,939 |
||||
| Non-GAAP adjustments: |
||||||||
| Amortization of intangible assets |
202 |
202 |
||||||
| Adjusted income before income tax provision |
2,085 |
2,141 |
||||||
| Adjusted income tax provision |
824 |
846 |
||||||
| Adjusted income from continuing operations |
1,261 |
1,295 |
||||||
| Net income attributable to noncontrolling interest |
(2) |
(2) |
||||||
| Income allocable to participating securities |
(6) |
(6) |
||||||
| Adjusted income from continuing operations attributable to CVS Health |
1,253 |
1,287 |
||||||
| Weighted average diluted shares outstanding |
1,098 |
1,098 |
||||||
| Adjusted earnings per share |
$ |
1.14 |
$ |
1.17 |
||||
| (1) Excludes acquisition-related integration costs for the acquisitions of Omnicare and the pharmacies and clinics of Target. |
||||||||
| Free Cash Flow Guidance |
||||||||
| (Unaudited) |
||||||||
| The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions. |
||||||||
| In millions |
Year Ending December 31, 2016 |
|||||||
| Net cash provided by operating activities |
$ |
7,575 |
$ |
7,875 |
||||
| Subtract: Additions to property and equipment |
(2,550) |
(2,450) |
||||||
| Add: Proceeds from sale-leaseback transactions |
275 |
175 |
||||||
| Free cash flow |
$ |
5,300 |
$ |
5,600 |
||||
Logo - http://photos.prnewswire.com/prnh/20140905/143455
SOURCE CVS Health
Share this article